Literature DB >> 25919256

Obesity is associated with increased health care charges in patients undergoing outpatient plastic surgery.

Michelle R Sieffert1, Justin P Fox, Lindsay E Abbott, R Michael Johnson.   

Abstract

BACKGROUND: Obesity is associated with greater rates of surgical complications. To address these complications after outpatient plastic surgery, obese patients may seek care in the emergency department and potentially require admission to the hospital, which could result in greater health care charges. The purpose of this study was to determine the relationship of obesity, postdischarge hospital-based acute care, and hospital charges within 30 days of outpatient plastic surgery.
METHODS: From state ambulatory surgery center databases in four states, all discharges for adult patients who underwent liposuction, abdominoplasty, breast reduction, and blepharoplasty were identified. Patients were grouped by the presence or absence of obesity. Multivariable regression models were used to compare the frequency of hospital-based acute care, serious adverse events, and hospital charges within 30 days between groups while controlling for confounding variables.
RESULTS: The final sample included 47,741 discharges, with 2052 of these discharges (4.3 percent) being obese. Obese patients more frequently had a hospital-based acute care encounter [7.3 percent versus 3.9 percent; adjusted OR, 1.35 (95% CI,1.13 to 1.61)] or serious adverse event [3.2 percent versus 0.9 percent; adjusted OR, 1.73 (95% CI, 1.30 to 2.29)] within 30 days of surgery. Obese patients had adjusted hospital charges that were, on average, $3917, $7412, and $7059 greater (p < 0.01) than those of nonobese patients after liposuction, abdominoplasty, and breast reduction, respectively.
CONCLUSION: Obese patients who undergo common outpatient plastic surgery procedures incur substantially greater health care charges, in part attributable to more frequent adverse events and hospital-based health care within 30 days of surgery. CLINICAL QUESTION/LEVEL OF EVIDENCE: Risk, II.

Entities:  

Mesh:

Year:  2015        PMID: 25919256     DOI: 10.1097/PRS.0000000000001155

Source DB:  PubMed          Journal:  Plast Reconstr Surg        ISSN: 0032-1052            Impact factor:   4.730


  2 in total

Review 1.  Oestrogen and anti-androgen therapy for transgender women.

Authors:  Vin Tangpricha; Martin den Heijer
Journal:  Lancet Diabetes Endocrinol       Date:  2016-12-02       Impact factor: 32.069

2.  Body Contouring Surgery: Our 5 Years Experience.

Authors:  Irene Zerini; Andrea Sisti; Laura Barberi; Roberto Cuomo; Juri Tassinari; Luca Grimaldi; Carlo D'Aniello; Giuseppe Nisi
Journal:  Plast Reconstr Surg Glob Open       Date:  2016-03-18
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.